Although a previous study has suggested that specific CFH polymorphisms may protect against severe renal involvement in IgAV by maintaining higher CFH levels [26], the absence of a significant difference between patients with and without nephritis in our cohort indicates that CFH alone may not serve as a reliable biomarker for predicting renal involvement. This evidence concerns the gene CFH and nephritis.